CorMedix, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:CRMD
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 448 out of 850
Universe
Global Universe 10197 out of 15081
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Basilea Pharmaceutica AG |
25.5
Medium
|
225 out of 850 |
Savara, Inc. |
25.8
Medium
|
242 out of 850 |
CureVac NV |
27.5
Medium
|
347 out of 850 |
Astria Therapeutics, Inc. |
28.3
Medium
|
405 out of 850 |
CorMedix, Inc. |
29.3
Medium
|
448 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
CorMedix, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
CorMedix, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted CorMedix, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level